Global Pulmonary Arterial Hypertension (PAH) Treatment Market is thriving due to a rising prevalence of pulmonary hypertension, advancements in drug development, increasing awareness about the disease ...

Teva's transformation boosts profit growth and specialty drugs, offering an undervalued opportunity. Click here to read my ...

Teva Pharmaceutical Industries TEVA reported second-quarter 2025 adjusted earnings of 66 cents per share, which beat the ...

Alvotech ALVO, a commercial-stage company developing and manufacturing biosimilar medicines for patients worldwide, is ...

Markets today await the Fed’s rate decision, key GDP data, and earnings from Meta, Microsoft, and Ford in a pivotal U.S.

Stocks rose to record highs on Friday as a busy week of earnings reports and trade-related news drew to a close.

Deckers Outdoor Corporation (DECK) delivered an impressive first-quarter fiscal 2026 performance, surpassing expectations and increasing year over year. The standout performances of its HOKA and UGG ...

Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2025: ...

The Global Fibromyalgia Treatment Market, valued at approximately USD 3.1 billion in 2022, is projected to grow at a healthy CAGR of more than 4.0% during the forecast period from 2023 to 2030. This ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

TEVA stock jumps 21.6% in three months on branded drug growth, biosimilar launches, and margin-boosting cost cuts.